Appeal 2007-1817
Application 10/045,510
Representative claims 1 and 95 read as follows:
1. A crystalline venlaflaxine base wherein the venlaflaxine base is in
the form of white crystals.
95. White crystalline solid venlafaxine base prepared by a method
comprising the steps of:
a) providing a solution of venlafaxine hydrochloride in water,
b) combining the solution of venlafaxine hydrochloride with sodium
hydroxide,
c) extracting the combination with an organic solvent to obtain extract,
d) drying the extract,
e) evaporating the extract to obtain a residue,
f) combining the residue with an alkane, and
g) crystallizing venlafaxine base that is a white crystalline solid from the
combination of residue and alkane.
Cited References:
Jerussi WO 00/32555 Jun. 8, 2000
Grounds of Rejection
Claims 1-2 and 95-98 are rejected under 35 U.S.C. § 103(a) as
obvious over Jerussi.
We affirm.
DISCUSSION
Venlafaxine is a commercial product sold prior to Appellants’ filing
date by Wyeth under the tradename EffexorŽ. Venlafaxine acts by
inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: September 9, 2013